Results 141 to 150 of about 1,662,629 (361)

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source

Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

Molecular Oncology, EarlyView.
Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren, Kathryn A. Wierenga, Frank M. Riemers, Elsbeth A. van Liere, Bart Westendorp   +4 more
wiley   +1 more source

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

Molecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh, Amelia Martinez Villarreal, Philippe Lefrançois, Jennifer Gantchev, Sriraam Sivachandran, Samy Abou Setah, Ivan V. Litvinov   +6 more
wiley   +1 more source

From Bench to Bedside: A Review of Clinical Trials in Drug Discovery and Development [PDF]

arXiv
Clinical trials are an indispensable part of the drug development process, bridging the gap between basic research and clinical application. During the development of new drugs, clinical trials are used not only to evaluate the safety and efficacy of the drug but also to explore its dosage, treatment regimens, and potential side effects.
arxiv  

CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma

Molecular Oncology, EarlyView.
CircCCNB1 expression is down‐regulated in nasopharyngeal carcinoma (NPC); thus, less NF90 protein is bound to circCCNB1 and more binds to pri‐miRNAs, blocking their (pri‐miRNAs) binding to DGCR8 and inhibiting the processing and generation of miR‐15b‐5p/miR‐7‐1‐3p. Furthermore, decreased miR‐15b‐5p/miR‐7‐1‐3p promotes the expression of the target genes
Chunmei Fan, Fenghua Tan, Jie Wu, Zhaoyang Zeng, Wenjia Guo, He Huang, Wei Xiong   +6 more
wiley   +1 more source

Classification of acute myeloid leukemia based on multi‐omics and prognosis prediction value

Molecular Oncology, EarlyView.
The Unsupervised AML Multi‐Omics Classification System (UAMOCS) integrates genomic, methylation, and transcriptomic data to categorize AML patients into three subtypes (UAMOCS1‐3). This classification reveals clinical relevance, highlighting immune and chromosomal characteristics, prognosis, and therapeutic vulnerabilities.
Yang Song, Zhe Wang, Guangji Zhang, Jiangxue Hou, Kaiqi Liu, Shuning Wei, Yan Li, Chunlin Zhou, Dong Lin, Min Wang, Hui Wei, Jianxiang Wang, Tao Cheng, Yingchang Mi   +13 more
wiley   +1 more source

Establishment of a Nationwide Patient Database for Clinical Trial Recruitment in Dermatology: Concept and Patient Characteristics

Acta Dermato-Venereologica, 2021
Dorra Bouazzi, Anette Bygum, Lone Skov, Mikkel Lindskov Sachs, Lars Iversen, Merete Hædersdal, Gregor B.E. Jemec, Simon F. Thomsen   +7 more
doaj   +1 more source

Management of Severe Infections: A Time to Keep a Cool Head or a Hot Topic for Clinical Trials? [PDF]

, 2014
Kevin B. Laupland, Louis Valiquette
openalex   +1 more source

Plasma lipidomic and metabolomic profiles in high‐grade glioma patients before and after 72‐h presurgery water‐only fasting

Molecular Oncology, EarlyView.
Presurgery 72‐h fasting in GB patients leads to adaptations of plasma lipids and polar metabolites. Fasting reduces lysophosphatidylcholines and increases free fatty acids, shifts triglycerides toward long‐chain TGs and increases branched‐chain amino acids, alpha aminobutyric acid, and uric acid.
Iris Divé, Lisa Hahnefeld, Katharina J. Wenger, Donat Kögel, Joachim Steinbach, Gerd Geisslinger, Michael W. Ronellenfitsch, Irmgard Tegeder   +7 more
wiley   +1 more source

Language Interaction Network for Clinical Trial Approval Estimation [PDF]

arXiv
Clinical trial outcome prediction seeks to estimate the likelihood that a clinical trial will successfully reach its intended endpoint. This process predominantly involves the development of machine learning models that utilize a variety of data sources such as descriptions of the clinical trials, characteristics of the drug molecules, and specific ...
arxiv